Literature DB >> 17538133

Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter.

Gerard J O'Sullivan1, Derek G Lohan, Niall Gough, Carmel G Cronin, Stephen T Kee.   

Abstract

PURPOSE: To evaluate the performance of the Trellis-8 isolated thrombolysis catheter during single-session pharmacomechanical thrombectomy (PMT) combined with low-dose thrombolysis with tissue plasminogen activator (TPA) in the treatment of patients with acute deep vein thrombosis (DVT) and multiple comorbidities.
MATERIALS AND METHODS: Retrospective analysis was performed of 19 consecutive patients with acute above-knee DVT treated by PMT with the Trellis device followed by venous angioplasty and stent placement. Isolated thrombolysis with low-dose TPA was used with all patients. Concurrent therapies included retrievable inferior vena cava filter insertion (n = 4). The primary endpoint was restoration of rapid inline venous flow; the secondary endpoint was thrombus clearance.
RESULTS: Restoration of rapid inline venous flow was achieved in all cases; thrombus removal was less than 50% in one case (4%), 50%-95% in 18 cases (82%), and at least 95% in three cases (14%). The median administered dose of TPA was 13.4 mg per patient. The mean treatment time was 91 minutes per limb (range, 61-129 min), with a mean of 21 minutes per thrombosed segment (range, 8-31 min). There were no major complications. Primary patency rate of the treated venous segments at 2 days was 86% (n = 19) and the primary assisted patency rate was 100% at 30 days. Two patients died of advanced malignancy at 17 and 24 days.
CONCLUSIONS: The Trellis system was an effective method for the treatment of acute DVT. Based on the present data, the Trellis system could prove to be a safe and feasible single-session PMT method for the treatment of acute DVT in a broader patient population and warrants further investigation in a large-scale study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538133     DOI: 10.1016/j.jvir.2007.03.013

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  17 in total

1.  Thrombolytic therapy for deep vein thrombosis.

Authors:  Suresh Vedantham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

Review 2.  Optional inferior vena caval filters: where are we now?

Authors:  A N Keeling; T B Kinney; M J Lee
Journal:  Eur Radiol       Date:  2008-04-02       Impact factor: 5.315

3.  Deep Vein Thrombosis of the Upper Extremity.

Authors:  Jan Heil; Wolfgang Miesbach; Thomas Vogl; Wolf O Bechstein; Alexander Reinisch
Journal:  Dtsch Arztebl Int       Date:  2017-04-07       Impact factor: 5.594

4.  Endovascular management of acute upper extremity deep venous thrombosis and the use of superior vena cava filters.

Authors:  Joseph P Koury; Charles T Burke
Journal:  Semin Intervent Radiol       Date:  2011-03       Impact factor: 1.513

Review 5.  Treating infrainguinal deep venous thrombosis.

Authors:  Suresh Vedantham
Journal:  Tech Vasc Interv Radiol       Date:  2014-06

Review 6.  Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME.

Authors:  Anthony J Comerota
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jul-Sep

7.  Total preservation of patency and valve function after percutaneous pharmacomechanical thrombolysis using the Trellis®-8 system for an acute, extensive deep venous thrombosis.

Authors:  J R Wormald; T R A Lane; P E Herbert; M Ellis; N J Burfitt; I J Franklin
Journal:  Ann R Coll Surg Engl       Date:  2012-03       Impact factor: 1.891

Review 8.  Endovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the Art.

Authors:  Akhilesh K Sista; Suresh Vedantham; John A Kaufman; David C Madoff
Journal:  Radiology       Date:  2015-07       Impact factor: 11.105

Review 9.  Thrombectomy and thrombolysis for the prevention and treatment of postthrombotic syndrome.

Authors:  Suresh Vedantham
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

10.  Biochemical dynamics relevant to the safety of low-dose, intraclot alteplase for deep vein thrombosis.

Authors:  Jay N Lozier; Ann M Cullinane; Khanh Nghiem; Richard Chang; McDonald K Horne
Journal:  Transl Res       Date:  2012-02-23       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.